Annual EBITDA
-$166.08 M
+$33.88 M+16.94%
31 December 2023
Summary:
Mersana Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$166.08 million, with the most recent change of +$33.88 million (+16.94%) on 31 December 2023. During the last 3 years, it has fallen by -$79.40 million (-91.61%). MRSN annual EBITDA is now -1161.43% below its all-time high of -$13.17 million, reached on 31 December 2016.MRSN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$9.70 M
+$13.19 M+57.63%
30 September 2024
Summary:
Mersana Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$9.70 million, with the most recent change of +$13.19 million (+57.63%) on 30 September 2024. Over the past year, it has increased by +$30.52 million (+75.89%). MRSN quarterly EBITDA is now -143.60% below its all-time high of $22.24 million, reached on 31 March 2019.MRSN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$68.51 M
+$30.52 M+30.82%
30 September 2024
Summary:
Mersana Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$68.51 million, with the most recent change of +$30.52 million (+30.82%) on 30 September 2024. Over the past year, it has increased by +$123.20 million (+64.27%). MRSN TTM EBITDA is now -1206.14% below its all-time high of -$5.25 million, reached on 31 March 2016.MRSN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRSN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.9% | +75.9% | +64.3% |
| 3 y3 years | -91.6% | +78.5% | +53.9% |
| 5 y5 years | -163.6% | +40.8% | -108.0% |
MRSN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -91.6% | +16.9% | at high | +83.5% | at high | +67.4% |
| 5 y | 5 years | -521.4% | +16.9% | at high | +83.5% | -156.3% | +67.4% |
| alltime | all time | -1161.4% | +16.9% | -143.6% | +83.5% | -1206.1% | +67.4% |
Mersana Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.70 M(-57.6%) | -$68.51 M(-30.8%) |
| June 2024 | - | -$22.88 M(+28.0%) | -$99.02 M(-23.3%) |
| Mar 2024 | - | -$17.88 M(-0.9%) | -$129.10 M(-22.3%) |
| Dec 2023 | -$166.08 M(-16.9%) | -$18.05 M(-55.1%) | -$166.08 M(-13.4%) |
| Sept 2023 | - | -$40.21 M(-24.1%) | -$191.71 M(-8.8%) |
| June 2023 | - | -$52.96 M(-3.5%) | -$210.22 M(+0.8%) |
| Mar 2023 | - | -$54.86 M(+25.6%) | -$208.49 M(+4.3%) |
| Dec 2022 | -$199.96 M(+19.1%) | -$43.68 M(-25.6%) | -$199.96 M(-2.0%) |
| Sept 2022 | - | -$58.72 M(+14.6%) | -$204.07 M(+7.1%) |
| June 2022 | - | -$51.23 M(+10.6%) | -$190.51 M(+5.9%) |
| Mar 2022 | - | -$46.33 M(-3.1%) | -$179.89 M(+7.1%) |
| Dec 2021 | -$167.94 M(+93.8%) | -$47.79 M(+5.8%) | -$167.94 M(+13.0%) |
| Sept 2021 | - | -$45.16 M(+11.2%) | -$148.64 M(+18.3%) |
| June 2021 | - | -$40.61 M(+18.1%) | -$125.62 M(+20.3%) |
| Mar 2021 | - | -$34.37 M(+20.7%) | -$104.46 M(+20.5%) |
| Dec 2020 | -$86.68 M | -$28.49 M(+28.7%) | -$86.67 M(+17.0%) |
| Sept 2020 | - | -$22.14 M(+13.8%) | -$74.06 M(+8.4%) |
| June 2020 | - | -$19.45 M(+17.3%) | -$68.29 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$16.59 M(+4.5%) | -$65.56 M(+145.3%) |
| Dec 2019 | -$26.73 M(-57.6%) | -$15.88 M(-3.0%) | -$26.73 M(-18.8%) |
| Sept 2019 | - | -$16.38 M(-2.0%) | -$32.93 M(-1.1%) |
| June 2019 | - | -$16.71 M(-175.2%) | -$33.29 M(+16.3%) |
| Mar 2019 | - | $22.24 M(-200.7%) | -$28.62 M(-54.8%) |
| Dec 2018 | -$63.00 M(+66.8%) | -$22.08 M(+32.0%) | -$63.36 M(+16.3%) |
| Sept 2018 | - | -$16.73 M(+38.8%) | -$54.46 M(+19.6%) |
| June 2018 | - | -$12.05 M(-3.7%) | -$45.55 M(+7.5%) |
| Mar 2018 | - | -$12.51 M(-5.2%) | -$42.38 M(+12.2%) |
| Dec 2017 | -$37.78 M(+186.9%) | -$13.19 M(+68.7%) | -$37.78 M(+63.0%) |
| Sept 2017 | - | -$7.82 M(-11.9%) | -$23.18 M(+10.0%) |
| June 2017 | - | -$8.88 M(+12.3%) | -$21.07 M(+33.1%) |
| Mar 2017 | - | -$7.90 M(-657.7%) | -$15.82 M(+20.2%) |
| Dec 2016 | -$13.17 M(-17.9%) | $1.42 M(-124.8%) | -$13.17 M(-9.7%) |
| Sept 2016 | - | -$5.71 M(+57.1%) | -$14.58 M(+64.3%) |
| June 2016 | - | -$3.63 M(-30.8%) | -$8.88 M(+69.2%) |
| Mar 2016 | - | -$5.25 M | -$5.25 M |
| Dec 2015 | -$16.04 M | - | - |
FAQ
- What is Mersana Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Mersana Therapeutics?
- What is Mersana Therapeutics annual EBITDA year-on-year change?
- What is Mersana Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly EBITDA year-on-year change?
- What is Mersana Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Mersana Therapeutics?
- What is Mersana Therapeutics TTM EBITDA year-on-year change?
What is Mersana Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MRSN is -$166.08 M
What is the all time high annual EBITDA for Mersana Therapeutics?
Mersana Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.17 M
What is Mersana Therapeutics annual EBITDA year-on-year change?
Over the past year, MRSN annual earnings before interest, taxes, depreciation & amortization has changed by +$33.88 M (+16.94%)
What is Mersana Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MRSN is -$9.70 M
What is the all time high quarterly EBITDA for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $22.24 M
What is Mersana Therapeutics quarterly EBITDA year-on-year change?
Over the past year, MRSN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$30.52 M (+75.89%)
What is Mersana Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MRSN is -$68.51 M
What is the all time high TTM EBITDA for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.25 M
What is Mersana Therapeutics TTM EBITDA year-on-year change?
Over the past year, MRSN TTM earnings before interest, taxes, depreciation & amortization has changed by +$123.20 M (+64.27%)